Bright Minds Biosciences Inc (DRUG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $61.99 (+0.71%), Market cap $0.77B, 52-week low–high $23.27 ~ $95.98.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration
Financial statements, price targets, institutional (13F) holdings and related news for Bright Minds Biosciences Inc are updated in real time on BlackAll Trade.
Bright Minds Biosciences Inc trades at $61.99 (+0.71%). Real-time quotes and charts are available on BlackAll Trade.
Bright Minds Biosciences Inc has a market cap of about $0.77B.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2